Clearmind Medicine Fails Nasdaq Equity Rule

TL;DR

Clearmind Medicine is out of compliance with Nasdaq's minimum equity rule, risking delisting.

AI Summary

Clearmind Medicine Inc. received a notification on November 3, 2025, from Nasdaq stating it is no longer in compliance with the Minimum Stockholders' Equity Rule (5550(b)(1)). This rule requires companies listed on the Nasdaq Capital Market to maintain a minimum stockholders' equity.

Why It Matters

Failure to regain compliance with Nasdaq listing rules could lead to delisting, impacting the company's ability to trade on the exchange and potentially affecting its stock value.

Risk Assessment

Risk Level: high — Non-compliance with Nasdaq listing rules poses a significant risk of delisting, which can severely impact stock liquidity and investor confidence.

Key Numbers

• 5550(b)(1) — Nasdaq Rule (This is the specific rule Clearmind Medicine is not in compliance with.)

Key Players & Entities

• Clearmind Medicine Inc. (company) — The company filing the report and subject to Nasdaq compliance.
• Nasdaq Stock Market LLC (company) — The exchange that issued the non-compliance notification.
• November 3, 2025 (date) — The date Clearmind Medicine received the notification.
• 5550(b)(1) (rule) — The specific Nasdaq Listing Rule regarding Minimum Stockholders' Equity.

FAQ

Key Financial Figures

• $2,500,000 — Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for conti
• $10,000,000 — the aggregate principal amount of up to $10,000,000. As of the date hereof, the Company has
• $2.5 m — es in the aggregate principal amount of $2.5 million, of which an aggregate of $2.2 mi
• $2.2 million — $2.5 million, of which an aggregate of $2.2 million of outstanding amounts due under the Pr
• $7.25 million — 2025, the Company raised approximately $7.25 million in gross proceeds from registered direc
• $183,000 — gregate gross proceeds of approximately $183,000. As of the date of this Report of Fore

Filing Documents

• ea0268533-6k_clearmind.htm (6-K) — 15KB
• 0001213900-25-118712.txt ( ) — 16KB

Forward-Looking Statements

Forward-Looking Statements This Report of Foreign Private Issuer on Form 6-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Forward-looking statements can be identified by words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of forward-looking statements in this Report of Foreign Private Issuer on Form 6-K include, without limitation, statements regarding the Company’s belief that it has regained compliance with the Minimum Stockholders’ Equity Rule and the Company’s ability to maintain compliance Nasdaq Listing Rules. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchang

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: December 5, 2025 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 2

View Full Filing

View this 6-K filing on SEC EDGAR